1
|
Wilson JR, Di Nicola M, Williams BK. Hematoma at the insertion of the medial rectus mimicking a conjunctival melanoma. J Fr Ophtalmol 2023; 46:417. [PMID: 36868937 DOI: 10.1016/j.jfo.2022.09.041] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/13/2022] [Accepted: 09/26/2022] [Indexed: 03/05/2023]
Affiliation(s)
- J R Wilson
- Department of Ophthalmology, University of Cincinnati College of Medicine, 231 Albert Sabin Way, Suite 5414, Cincinnati, OH, 45267-0527 Ohio, USA
| | - M Di Nicola
- Department of Ophthalmology, University of Cincinnati College of Medicine, 231 Albert Sabin Way, Suite 5414, Cincinnati, OH, 45267-0527 Ohio, USA
| | - B K Williams
- Department of Ophthalmology, University of Cincinnati College of Medicine, 231 Albert Sabin Way, Suite 5414, Cincinnati, OH, 45267-0527 Ohio, USA; Cincinnati Eye Institute, Cincinnati, OH, USA.
| |
Collapse
|
2
|
Costantini E, Carrarini C, Borrelli P, De Rosa M, Calisi D, Consoli S, D’Ardes D, Cipollone F, Di Nicola M, Onofrj M, Reale M, Bonanni L. Different peripheral expression patterns of the nicotinic acetylcholine receptor in dementia with Lewy bodies and Alzheimer's disease. Immun Ageing 2023; 20:3. [PMID: 36647139 PMCID: PMC9843938 DOI: 10.1186/s12979-023-00329-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/19/2022] [Accepted: 11/26/2022] [Indexed: 01/18/2023]
Abstract
BACKGROUND The diffuse distribution of nicotinic cholinergic receptors (nAChRs) in both brain and peripheral immune cells points out their involvement in several pathological conditions. Indeed, the deregulated function of the nAChR was previously correlated with cognitive decline and neuropsychiatric symptoms in Alzheimer's disease (AD) and Dementia with Lewy bodies (DLB). The evaluation in peripheral immune cells of nAChR subtypes, which could reflect their expression in brain regions, is a prominent investigation area. OBJECTIVES This study aims to evaluate the expression levels of both the nAChR subunits and the main known inflammatory cytokines in peripheral blood mononuclear cells (PBMCs) of patients with DLB and AD to better characterize their involvement in these two diseases. RESULTS Higher gene expression levels of TNFα, IL6 and IL1β were observed in DLB and AD patients in comparison with healthy controls (HC). In our cohort, a reduction of nAChRα4, nAChRβ2 and nAChRβ4 was detected in both DLB and AD with respect to HC. Considering nAChR gene expressions in DLB and AD, significant differences were observed for nAChRα3, nAChRα4, nAChRβ2 and nAChRβ4 between the two groups. Moreover, the acetylcholine esterase (AChE) gene expression was significantly higher in DLB than in AD. Correlation analysis points out the relation between different nAChR subtype expressions in DLB (nAChRβ2 vs nAChRα3; nAChRα4 vs nAChRα3) and AD (nAChRα4 vs nAChRα3; nAChRα4 vs nAChRβ4; nAChRα7 vs nAChRα3; nAChRα7 vs nAChRα4). CONCLUSIONS Different gene expressions of both pro-inflammatory cytokines and nAChR subtypes may represent a peripheral link between inflammation and neurodegeneration. Inflammatory cytokines and different nAChRs should be valid and accurate peripheral markers for the clinical diagnosis of DLB and AD. However, although nAChRs show a great biological role in the regulation of inflammation, no significant correlation was detected between nAChR subtypes and the examined cytokines in our cohort of patients.
Collapse
Affiliation(s)
- E. Costantini
- grid.412451.70000 0001 2181 4941Department of Medicine and Aging Sciences, University “G. d’Annunzio”, Via dei Vestini, 66100 Chieti, Italy
| | - C. Carrarini
- grid.412451.70000 0001 2181 4941Department of Neuroscience, Imaging, and Clinical Sciences, “G. d’Annunzio” University of Chieti-Pescara, Chieti, Italy
| | - P. Borrelli
- grid.412451.70000 0001 2181 4941Department of Medical, Oral and Biotechnological Sciences, Laboratory of Biostatistics, University “G. d’Annunzio”, Via dei Vestini, 66100 Chieti, Italy
| | - M. De Rosa
- grid.412451.70000 0001 2181 4941Department of Neuroscience, Imaging, and Clinical Sciences, “G. d’Annunzio” University of Chieti-Pescara, Chieti, Italy
| | - D. Calisi
- grid.412451.70000 0001 2181 4941Department of Neuroscience, Imaging, and Clinical Sciences, “G. d’Annunzio” University of Chieti-Pescara, Chieti, Italy
| | - S. Consoli
- grid.412451.70000 0001 2181 4941Department of Neuroscience, Imaging, and Clinical Sciences, “G. d’Annunzio” University of Chieti-Pescara, Chieti, Italy
| | - D. D’Ardes
- grid.412451.70000 0001 2181 4941Department of Medicine and Aging Sciences, University “G. d’Annunzio”, Via dei Vestini, 66100 Chieti, Italy
| | - F. Cipollone
- grid.412451.70000 0001 2181 4941Department of Medicine and Aging Sciences, University “G. d’Annunzio”, Via dei Vestini, 66100 Chieti, Italy
| | - M. Di Nicola
- grid.412451.70000 0001 2181 4941Department of Medical, Oral and Biotechnological Sciences, Laboratory of Biostatistics, University “G. d’Annunzio”, Via dei Vestini, 66100 Chieti, Italy
| | - M. Onofrj
- grid.412451.70000 0001 2181 4941Department of Neuroscience, Imaging, and Clinical Sciences, “G. d’Annunzio” University of Chieti-Pescara, Chieti, Italy
| | - M. Reale
- grid.412451.70000 0001 2181 4941Department of Innovative Technologies in Medicine and Dentistry, University “G. d’Annunzio”, Via dei Vestini, 66100 Chieti, Italy
| | - L. Bonanni
- grid.412451.70000 0001 2181 4941Department of Medicine and Aging Sciences, University “G. d’Annunzio”, Via dei Vestini, 66100 Chieti, Italy
| |
Collapse
|
3
|
Perez-Gracia JL, Penel N, Calvo E, Awada A, Arkenau HT, Amaral T, Grünwald V, Sanmamed MF, Castelo-Branco L, Bodoky G, Lolkema MP, Di Nicola M, Casali P, Giuliani R, Pentheroudakis G. Streamlining clinical research: an ESMO awareness call to improve sponsoring and monitoring of clinical trials. Ann Oncol 2023; 34:70-77. [PMID: 36209982 DOI: 10.1016/j.annonc.2022.09.162] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/08/2022] [Revised: 09/22/2022] [Accepted: 09/28/2022] [Indexed: 02/03/2023] Open
Abstract
BACKGROUND During recent years, the burden of bureaucracy in clinical research has increased dramatically, adversely impacting the activity of investigators and clinical research teams. Although compliance with the Declaration of Helsinki, the guidelines for Good Clinical Practice (GCP), and other applicable regulations remains unquestionable, their overinterpretation and substitution by the internal operating procedures of sponsors and Contract Research Organizations (CROs) have increased the administrative burden. A survey conducted by the European Society for Medical Oncology (ESMO) Clinical Research Observatory (ECRO) among 940 investigators confirmed that they considered that the administrative burden in clinical research is excessive; that administrative procedures could be reduced without affecting the safety and the rights of the patients and the quality of the data; and that bureaucracy represents an obstacle for clinical research. METHODS A panel of physicians with extensive experience in clinical research, composed by members of the ECRO and the ESMO Scientific Medical and Public Policy divisions, analyzed clinical trial procedures related to administrative workflow, pharmacovigilance, and medical care. RESULTS The panel identified situations that generate debate between investigators and sponsors/CROs and selected real clinical scenarios that exemplify such situations. The panel discussed and proposed specific recommendations for those situations, based on GCP. CONCLUSIONS This initiative aspires to streamline clinical research procedures and to become a platform for discussion among all clinical trial stakeholders, with the aim of promoting the sustainability of clinical research and the care of cancer patients.
Collapse
Affiliation(s)
- J L Perez-Gracia
- Department of Oncology, University Clinic of Navarra and Health Research Institute of Navarra (IdiSNA), Pamplona, Spain.
| | - N Penel
- Centre Oscar Lambret and Lille University, Lille, France
| | - E Calvo
- START Madrid-CIOCC, Centro Integral Oncológico Clara Campal, Madrid, Spain
| | - A Awada
- Institut Jules Bordet, Université Libre de Bruxelles (Head of the Oncology Medicine Department), Brussels, Belgium
| | | | - T Amaral
- Division of Dermato-Oncology, Department of Dermatology, University of Tuebingen, Tuebingen, Germany; Cluster of Excellence iFIT (EXC 2180) 'Image Guided and Functionally Instructed Tumor Therapies', Tuebingen, Germany
| | - V Grünwald
- University Hospital Essen, Clinic for Medical Oncology and Clinic for Urology, Essen, Germany
| | - M F Sanmamed
- Department of Oncology, University Clinic of Navarra and Health Research Institute of Navarra (IdiSNA), Pamplona, Spain
| | - L Castelo-Branco
- Scientific and Medical Division, ESMO - European Society for Medical Oncology, 6900 - Lugano, Switzerland; NOVA National School of Public Health, NOVA University, Lisbon, Portugal
| | | | - M P Lolkema
- Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, the Netherlands
| | - M Di Nicola
- Immunotherapy and Innovative Therapeutics Unit, Oncology and Hematology Department Fondazione, IRCCS Istituto Nazionale Tumori, Milan, Italy
| | - P Casali
- Fondazione IRCCS Istituto Nazionale Tumori and University of Milan, Milan, Italy
| | - R Giuliani
- The Clatterbridge Cancer Centre, Liverpool, UK
| | - G Pentheroudakis
- Scientific and Medical Division, European Society for Medical Oncology, Lugano, Switzerland
| |
Collapse
|
4
|
Marchioni M, Porreca A, Di Nicola M, Lucarelli G, Dorin V, Soria F, Terracciano D, Mistretta F, Buonerba C, Cantiello F, Cantiello F, Mari A, Minervini A, Veccia A, Musi G, Hurle R, Busetto G, Del Giudice F, Chung B, Berardinelli F, Perdonà S, Del Prete P, Mirone V, Borghesi M, Porreca A, Bove P, Autorino R, Crisan N, Battaglia M, Ditonno P, Russo G, Muto M, Damiano R, Porpiglia F, de Cobelli O, Schips L, Ferro M. Progression-free survival as surrogate endpoint in high-risk non-muscle invasive bladder cancer studies: results from a machine learning-based analysis of a large multi-institutional database. EUR UROL SUPPL 2022. [DOI: 10.1016/s2666-1683(22)01228-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
|
5
|
Tafuri A, Marchioni M, Cerrato C, Mari A, Tellini R, Odorizzi K, Veccia A, Amparore D, Shakir A, Carbonara U, Trovato F, Catellani M, Janello L, Bianchi L, Novara G, Dal Moro F, Schiavina R, De Lorenzis E, Parma P, Cimino S, de Cobelli O, Maiorino F, Bove P, Crocerossa F, Cantiello F, D’andrea D, Di Cosmo F, Porpiglia F, Ditonno P, Montanari E, Soria F, Gontero P, Liguori G, Trombetta C, Mantica G, Borghesi M, Terrone C, Del Giudice F, Sciarra A, Galosi A, Moschini M, Shariat S, Di Nicola M, Minervini A, Ferro M, Cerruto M, Schips L, Pagliarulo V, Antonelli A. Changes in renal function after nephroureterectomy for upper urinary tract carcinoma: analysis of a large multicenter cohort (radical nephroureterectomy outcomes (RANEO) research consortium). EUR UROL SUPPL 2022. [DOI: 10.1016/s2666-1683(22)01230-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
6
|
Costantini E, Aielli L, Ferretti S, De Palma A, Ciavarella D, Litterio G, Reale M, Di Nicola M, Schips L, Marchioni M. Synergistic effects of curcumin and lactoferrin to inhibit the prostatic cancer cells growth and migration ability. EUR UROL SUPPL 2022. [DOI: 10.1016/s2666-1683(22)01981-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
7
|
Simonetti A, Bernardi E, Bartolucci G, Ferrara O, Ruggiero S, Di Nicola M, Janiri D, Sani G. Cognitive correlates of mixed depression. Eur Psychiatry 2022. [PMCID: PMC9566389 DOI: 10.1192/j.eurpsy.2022.261] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
Abstract
Introduction Mixed depressive states portend greater rates of impulsivity, attempted suicide, treatment resistance, and poorer outcome than non-mixed forms of depression. The neurocognitive bases of such affective states have not been defined yet. Objectives This work represents an attempt to clarify the neuropsychology underlying mixed depressive states. Methods Thirty subjects with affective disorders with mixed depression (MxD), 54 subjects with non-mixed depression (nonMxD), 73 euthymic subjects (Eu) and 93 healthy comparisons (HC) underwent a neurocognitive battery including the Trail-Making Test (TMT), the Controlled Word Fluency Test (WFT) and the Semantic Fluency Test (SFT), the Wisconsin Card Sorting Test (WCST, the Rey Auditory Verbal Learning Test RAVLT, the Rey-Osterrieth Complex Figure Test ROCFT, the Raven’s Progressive Matrices (RPM), and the Interference Component of the Stroop Test (ST). Between-group differences were performed through multiple one-way analyses of variance. Post-hoc analyses were performed using Tukey post-hoc tests. Results HC performed better than the three patient groups in all the aforementioned neurocognitive tests. Eu performed better in RPM, TMT, SFT than nonMxD, and better on ST WCST than both nonMxD and MxD. MxD showed better performances in RPM, TMT-A, WCST than nonMxD, and more errors and less reaction times in the ST than nonMxD. Conclusions
Mixed depressive states are characterized by enhanced attentional resources and greater set shifting abilities than non-mixed depressive states. On the other hand, they have less cognitive control than non-mixed depression. Such findings might explain some typical features observed in subjects with mixed depression, such impulsivity, suicidality, emotional reactivity and behavioral dyscontrol. Disclosure No significant relationships.
Collapse
|
8
|
Franco P, Porreca A, Di Nicola M, Mantello G, Valvo F, Slim N, Manfrida S, Gambacorta M, De Felice F, Vagge S, Krengli M, Palazzari E, Osti M, Gonelli A, Catalano G, Pittoni P, Lupattelli M, Niespolo M, Rosetto M, Macchia G, Durante O, Munoz F, D'Angelillo R, Genovesi D, Caravatta L. OC-0272 External validation of the Hemo-Eosinophils-Inflammation index as a prognosticator in anal cancer. Radiother Oncol 2022. [DOI: 10.1016/s0167-8140(22)02530-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
9
|
Di Guglielmo F, Trignani M, Lucarelli M, Caravatta L, Porreca A, Di Nicola M, Genovesi D. PO-1358 Neutrophil-To-Lymphocyte Ratio Predicts Recurrence And Response In Stereotactic Brain Radiotherapy. Radiother Oncol 2022. [DOI: 10.1016/s0167-8140(22)03322-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
10
|
Gasparini L, Borgia M, Trignani M, Di Pilla A, Porreca A, Di Nicola M, Genovesi D. PO-1073 NLR and PLR ratio as predictive markers of outcomes in head and neck squamous cell carcinoma. Radiother Oncol 2022. [DOI: 10.1016/s0167-8140(22)03037-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
11
|
Tafuri A, Marchioni M, Cerrato C, Mari A, Veccia A, Parma P, Dal Moro F, Schiavina R, Bove P, Cantiello F, Porpiglia F, Ditonno P, Montanari E, Gontero P, Trombetta C, Terrone C, Schips L, Sciarra A, Galosi A, Ferro M, Shariat S, Di Nicola M, Minervini A, Pagliarulo V, Antonelli A. Renal function variation after nephroureterectomy for upper urinary tract carcinoma: Evaluation in a large multicenter cohort (Radical Nephroureterectomy Outcomes (RaNeO) Research Consortium). Eur Urol 2022. [DOI: 10.1016/s0302-2838(22)00380-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
12
|
Lombardi M, Molisana M, Genovesi E, De Innocentiis C, Limbruno U, Misuraca L, Di Vito L, Zimarino M, Renda G, Di Nicola M, De Caterina R. Prevention of contrast-induced nephropathy with urine alkalinization: the TEATE study. Eur Heart J 2021. [DOI: 10.1093/eurheartj/ehab724.2919] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Background
Contrast-induced acute kidney injury (CI-AKI) after coronary angiography and percutaneous interventions (PCI) impacts on hospitalization duration and mortality. Pre-procedural hydration is the sole strategy currently recommended for preventing CI-AKI. The role of sodium bicarbonate (SB) although attractive, since urine alkalinization suppresses the production of reactive oxygen species, is still controversial, and the optimal dosing to attain adequate urine alkalinization is still undefined.
Purpose
The PrevenTion of contrast-inducEd nephropathy with urine alkalinization (TEATE) study was a prospective 3-center 3-arm single-blind randomized controlled trial testing the hypothesis that adequate urine alkalinization is associated with CI-AKI prevention. Secondary endpoints were the efficacy of SB vs saline in achieving adequate urine alkalinization and reducing the incidence of CI-AKI compared with saline.
Methods
Patients candidate to coronary angiography and/or PCI with moderate-to-severe chronic kidney disease [eGFR of 15 to 60 mL/min/1.73 m2, by the Modification of Diet in Renal Disease Study equation (MDRD)] were randomly assigned to saline hydration (control), oral SB or i.v. SB. The study protocol was registered. We evaluated urinary pH at the time of hospitalization, immediately before coronary angiography and 24–48 hours after angiography. According to urine pH immediately before the procedure, patients were divided in two groups above or below a pH cut-off of 6.
Results
We enrolled a total of 241 patients: 81 were randomly assigned to the control group, 82 to i.v. SB and 78 to oral SB. Patients achieving a urinary pH >6 before angiography had a lower incidence of CI-AKI (46%) than patients with urinary pH ≤6 (54%) [OR=0.48 (95% CI 0.25–0.9) p=0.023]. The number of patients with urine pH >6 was higher in both the i.v. (71%) and the oral SB (65%) groups compared to the hydration-only group (44%, p=0.004). We found however no difference in the incidence of CI-AKI in the 3 treatment arms (20% in hydration alone, 21% in oral SB group and 22% in iv SB group) (p=0.94). Subgroup analyses according to basal urine pH and eGFR ranges failed to identify statistically significant differences in the development of CI-AKI according to treatment allocation.
Conclusions
Urinary pH before the administration of contrast medium is an inverse correlate of CI-AKI incidence, and SB is superior to hydration alone in achieving urinary alkalinization. Since, however, SB did not reduce the incidence of CI-AKI, we conclude that urinary pH is a marker and not a mediator of CI-AKI.
Funding Acknowledgement
Type of funding sources: None.
Collapse
Affiliation(s)
- M Lombardi
- G. d Annunzio University, Institute of Cardiology, Chieti, Italy
| | - M Molisana
- G. d Annunzio University, Institute of Cardiology, Chieti, Italy
| | - E Genovesi
- G. d Annunzio University, Institute of Cardiology, Chieti, Italy
| | - C De Innocentiis
- G. d Annunzio University, Institute of Cardiology, Chieti, Italy
| | - U Limbruno
- Azienda USL Toscana Sud Est, Cardiology Department, Grosseto, Italy
| | - L Misuraca
- Azienda USL Toscana Sud Est, Cardiology Department, Grosseto, Italy
| | - L Di Vito
- Cardiology ASUR-AV5 Mazzoni Hospital, Ascoli Piceno, Italy
| | - M Zimarino
- G. d Annunzio University, Institute of Cardiology, Chieti, Italy
| | - G Renda
- G. d Annunzio University, Institute of Cardiology, Chieti, Italy
| | - M Di Nicola
- G. d Annunzio University, Department of Medical, Oral and Biotechnological Sciences, Chieti, Italy
| | - R De Caterina
- University of Pisa, Institute of Cardiology, Pisa, Italy
| |
Collapse
|
13
|
Cantò C, Pennese E, Di Nicola M, Ricciuti G, Restuccia F, Luciani S, Angrilli F. 838P Rituximab and non-pegylated liposomial doxorubincin (R-NPLD) treatment in patients 80 years of age or older affected by diffuse large B-cell lymphoma (DLBCL): A 2020 update and implications of clinical and pathological factors. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.131] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
14
|
Di Guglielmo F, Ursini L, Nuzzo M, Rosa C, Di Tommaso M, Trignani M, Borgia M, Allajbej A, Patani F, Di Carlo C, Porreca A, Di Nicola M, Genovesi D, Caravatta L. PO-1137 A prospective study on Quality of life in patients treated with radiotherapy for early breast cancer. Radiother Oncol 2021. [DOI: 10.1016/s0167-8140(21)07588-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
15
|
Rossi I, D'Ardes D, Bucciarelli B, Allegra M, Guagnano M, Santilli F, Bianco F, Marchioni M, Di Nicola M, Cipollone F, Bucci M. Cholesterol and COVID-19: Findings from lipid profile of patients with SARS-COV-2 infection. Atherosclerosis 2021. [PMCID: PMC8415859 DOI: 10.1016/j.atherosclerosis.2021.06.393] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
16
|
Cantò C, Pennese E, Di Nicola M, Ricciuti G, Restuccia F, Luciani S, Angrilli F. RITUXIMAB AND NONPEGYLATED LIPOSOMIAL DOXORUBINCIN (R‐NPLD) TREATMENT IN PATIENTS 80 YEARS OF AGE OR OLDER AFFECTED BY DIFFUSE LARGE B CELL LYMPHOMA (DLBCL): A 2020 UPDATE AND IMPLICATIONS OF CLINICAL AND PATHOLOGICAL FACTORS. Hematol Oncol 2021. [DOI: 10.1002/hon.64_2881] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- C. Cantò
- Civic Hospital "Santo Spirito" Pescara Center for the Diagnosis and Treatment of Lymphomas Department of Oncology and Hematology Pescara Italy
| | - E. Pennese
- Civic Hospital "Santo Spirito" Pescara Center for the Diagnosis and Treatment of Lymphomas Department of Oncology and Hematology Pescara Italy
| | - M. Di Nicola
- “G. d'Annunzio” University Department of Medical, Oral and Biotechnological Sciences Chieti Italy
| | - G. Ricciuti
- IRCCS "Casa Sollievo della Sofferenza" Department of Hematology San Giovanni Rotondo FG Italy
| | - F. Restuccia
- Civic Hospital "Santo Spirito" Pescara Center for the Diagnosis and Treatment of Lymphomas Department of Oncology and Hematology Pescara Italy
| | - S. Luciani
- Civic Hospital "Santo Spirito" Pescara Center for the Diagnosis and Treatment of Lymphomas Department of Oncology and Hematology Pescara Italy
| | - F. Angrilli
- Civic Hospital "Santo Spirito" Pescara Center for the Diagnosis and Treatment of Lymphomas Department of Oncology and Hematology Pescara Italy
| |
Collapse
|
17
|
De Santis F, Romero-Cordoba S, Castagnoli L, Volpari T, Faraci S, Fucà G, Cerchietti L, Tagliabue E, De Braud F, Pupa S, Di Nicola M. 17P BCL6 and Notch pathway: A signaling axis leading to a novel druggable biotarget in triple-negative breast cancer. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.01.030] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
|
18
|
Fucà G, Spagnoletti A, Ambrosini M, de Braud F, Di Nicola M. Immune cell engagers in solid tumors: promises and challenges of the next generation immunotherapy. ESMO Open 2021; 6:100046. [PMID: 33508733 PMCID: PMC7841318 DOI: 10.1016/j.esmoop.2020.100046] [Citation(s) in RCA: 19] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/02/2020] [Revised: 12/16/2020] [Accepted: 12/23/2020] [Indexed: 12/22/2022] Open
Abstract
In the landscape of cancer immunotherapy, immune cell engagers (ICEs) are rapidly emerging as a feasible and easy-to-deliver alternative to adoptive cell therapy for the antitumor redirection of immune effector cells. Even if in hematological malignancies this class of new therapeutics already hit the clinic, the development of ICEs in solid tumors still represents a challenge. Considering that ICEs are a rapidly expanding biotechnology in cancer therapy, we designed this review as a primer for clinicians, focusing on the major obstacles for the clinical implementation and the most translatable approaches proposed to overcome the limitations in solid tumors.
Collapse
Affiliation(s)
- G Fucà
- Immunotherapy and Innovative Therapeutics Unit, Medical Oncology and Hematology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
| | - A Spagnoletti
- Immunotherapy and Innovative Therapeutics Unit, Medical Oncology and Hematology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - M Ambrosini
- Immunotherapy and Innovative Therapeutics Unit, Medical Oncology and Hematology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - F de Braud
- Immunotherapy and Innovative Therapeutics Unit, Medical Oncology and Hematology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; Oncology and Hemato-oncology Department, University of Milan, Milan, Italy
| | - M Di Nicola
- Immunotherapy and Innovative Therapeutics Unit, Medical Oncology and Hematology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| |
Collapse
|
19
|
Paz-Ares L, Kim T, Vicente D, Felip E, Lee D, Lee K, Lin CC, Flor M, Di Nicola M, Alvarez R, Helwig C, Ojalvo L, Gulley J, Cho B. MO01.27 Three-Year Follow-up of Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, as Second-Line (2L) Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC). J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2020.10.132] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
20
|
Franzago M, Lanuti P, Fraticelli F, Marchioni M, Buca D, Di Nicola M, Liberati M, Miscia S, Stuppia L, Vitacolonna E. Biological insight into the extracellular vesicles in women with and without gestational diabetes. J Endocrinol Invest 2021; 44:49-61. [PMID: 32335856 DOI: 10.1007/s40618-020-01262-0] [Citation(s) in RCA: 13] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/28/2019] [Accepted: 04/16/2020] [Indexed: 01/06/2023]
Abstract
PURPOSE Gestational diabetes mellitus (GDM) is the most common metabolic disorder in pregnancy, with increasing prevalence worldwide and still unclear pathogenic mechanisms. Extracellular vesicles (EVs) are emerging as potential biomarkers of disease-specific pathways in metabolic disorders, but their potential role in GDM is not fully understood. Therefore, the main aim of this study was to evaluate the link between EVs and hyperglycaemia during pregnancy. METHODS We assessed 50 GDM women and 50 controls at the third trimester of pregnancy in whom we collected demographic characteristics and clinical and anthropometric parameters. In addition, the circulating total EVs (tEVs) and their subpopulations were assessed using flow cytometry. RESULTS The levels of tEVs and EVs subtypes, expressed as median and interquartile range, were not significantly different between two groups; however, adipocyte-derived EVs (aEVs) concentration, expressed as percentage, was higher in controls than in GDM women (p = 0.045). In addition, a significant correlation was observed between aEVs (%) and third trimester total cholesterol (p = 0.022) within the GDM group. Furthermore, a significant correlation between endothelial-derived EVs (eEVs) and platelet-derived EVs (pEVs) within both groups was found, as well as a significant relation between aEVs and pEVs. CONCLUSIONS These data, although preliminary, represent the starting point for further studies to determine the role of circulating EVs in GDM.
Collapse
Affiliation(s)
- M Franzago
- Department of Medicine and Aging, School of Medicine and Health Sciences, "G. D'Annunzio" University, Chieti-Pescara, Via dei Vestini, 66100, Chieti, Italy
- Center for Advanced Studies and Technology (CAST), "G. D'Annunzio" University, Chieti-Pescara, Chieti, Italy
| | - P Lanuti
- Department of Medicine and Aging, School of Medicine and Health Sciences, "G. D'Annunzio" University, Chieti-Pescara, Via dei Vestini, 66100, Chieti, Italy
- Center for Advanced Studies and Technology (CAST), "G. D'Annunzio" University, Chieti-Pescara, Chieti, Italy
| | - F Fraticelli
- Department of Medicine and Aging, School of Medicine and Health Sciences, "G. D'Annunzio" University, Chieti-Pescara, Via dei Vestini, 66100, Chieti, Italy
- Center for Advanced Studies and Technology (CAST), "G. D'Annunzio" University, Chieti-Pescara, Chieti, Italy
| | - M Marchioni
- Laboratory of Biostatistics, Department of Medical, Oral and Biotechnological Sciences, "G. D'Annunzio" University, Chieti-Pescara, Chieti, Italy
| | - D Buca
- Department of Obstetrics and Gynaecology, SS. Annunziata Hospital, "G. D'Annunzio" University, Chieti-Pescara, Chieti, Italy
| | - M Di Nicola
- Laboratory of Biostatistics, Department of Medical, Oral and Biotechnological Sciences, "G. D'Annunzio" University, Chieti-Pescara, Chieti, Italy
| | - M Liberati
- Department of Medicine and Aging, School of Medicine and Health Sciences, "G. D'Annunzio" University, Chieti-Pescara, Via dei Vestini, 66100, Chieti, Italy
| | - S Miscia
- Department of Medicine and Aging, School of Medicine and Health Sciences, "G. D'Annunzio" University, Chieti-Pescara, Via dei Vestini, 66100, Chieti, Italy
- Center for Advanced Studies and Technology (CAST), "G. D'Annunzio" University, Chieti-Pescara, Chieti, Italy
| | - L Stuppia
- Center for Advanced Studies and Technology (CAST), "G. D'Annunzio" University, Chieti-Pescara, Chieti, Italy
- Department of Psychological, Health and Territorial Sciences, School of Medicine and Health Sciences, "G. D'Annunzio" University, Chieti-Pescara, Chieti, Italy
| | - E Vitacolonna
- Department of Medicine and Aging, School of Medicine and Health Sciences, "G. D'Annunzio" University, Chieti-Pescara, Via dei Vestini, 66100, Chieti, Italy.
- Center for Advanced Studies and Technology (CAST), "G. D'Annunzio" University, Chieti-Pescara, Chieti, Italy.
| |
Collapse
|
21
|
Rosa C, Gasparini L, Di Guglielmo F, Delli Pizzi A, Seccia B, Cianci R, Basilico R, Augurio A, Ursini L, Porreca A, Di Nicola M, Caravatta L, Genovesi D. OC-0567: T2 and Apparent Diffusion Coefficient MRI for Cervical cancer delineation: agreement between volumes. Radiother Oncol 2020. [DOI: 10.1016/s0167-8140(21)00589-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
22
|
Paz-Ares L, Kim T, Vicente D, Felip E, Lee D, Lee K, Lin CC, Flor M, Di Nicola M, Alvarez R, Helwig C, Ojalvo L, Gulley J, Cho B. 1272P Three-year follow-up of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, for second-line (2L) treatment of non-small cell lung cancer (NSCLC). Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.1586] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
23
|
Volpari T, De Santis F, Bracken AP, Pupa SM, Buschbeck M, Wegner A, Di Cosimo S, Lisanti MP, Dotti G, Massaia M, Pruneri G, Anichini A, Fortunato O, De Braud F, Del Vecchio M, Di Nicola M. Anticancer innovative therapy: Highlights from the ninth annual meeting. Cytokine Growth Factor Rev 2019; 51:1-9. [PMID: 31862236 DOI: 10.1016/j.cytogfr.2019.12.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
The Ninth Annual Conference of "Anticancer Innovative Therapy", organized by Fondazione IRCCS Istituto Nazionale dei Tumori di Milano (Fondazione IRCCS INT) and hosted by Hotel Michelangelo, was held in Milan on 25 January 2019. Cutting-edge science was presented in two main scientific sessions: i) pre-clinical evidences and new targets, and ii) clinical translation. The Keynote lecture entitled "Cancer stem cells (CSCs): metabolic strategies for their identification and eradication" presented by M. Lisanti, was one of the highlights of the conference. One key concept of the meeting was how the continuous advances in our knowledge about molecular mechanisms in various fields of research (cancer metabolism reprogramming, epigenetic regulation, transformation/invasiveness, and immunology, among others) are driving cancer research towards more effective personalized antineoplastic strategies. Specifically, recent preclinical data on the following topics were discussed: 1. Polycomb group proteins in cancer; 2. A d16HER2 splice variant is a flag of HER2 addiction across HER2-positive cancers; 3. Studying chromatin as a nexus between translational and basic research; 4. Metabolomic analysis in cancer patients; 5. CDK4-6 cyclin inhibitors: clinical activity and future perspectives as immunotherapy adjuvant; and 6. Cancer stem cells (CSCs): metabolic strategies for their identification and eradication. In terms of clinical translation, several novel approaches were presented: 1. Developing CAR-T cell therapies: an update of preclinical and clinical development at University of North Carolina; 2. Vγ9Vδ2 T-cell activation and immune suppression in multiple myeloma; 3. Predictive biomarkers for real-world immunotherapy: the cancer immunogram model in the clinical arena; and 4. Mechanisms of resistance to immune checkpoint blockade in solid tumors. Overall, the pre-clinical and clinical findings presented could pave the way to identify novel actionable therapeutic targets to significantly enhance the care of persons with cancer.
Collapse
Affiliation(s)
- T Volpari
- Immunotherapy and Innovative Therapeutics Unit, Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - F De Santis
- Immunotherapy and Innovative Therapeutics Unit, Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - A P Bracken
- Smurfit Institute of Genetics, Trinity College Dublin, Dublin 2, Ireland
| | - S M Pupa
- Molecular Targeting Unit, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - M Buschbeck
- Josep Carreras Leukemia Research Institute (IJC), Campus ICO-Germans Trias I Pujol, Universitat Autònoma de Barcelona, Badalona, Spain
| | - A Wegner
- Technische Universiät Braunschweig, Department of Bioinfomatics and Biochemistry and Braunschweig Integrated Center of Systems Biology (BRICS), Rebenring 56, 38106, Braunschweig, Germany
| | - S Di Cosimo
- Department of Applied Research and Technological Development, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - M P Lisanti
- Translational Medicine, Biomedical Research Centre, School of Environment and Life Sciences, University of Salford, Greater Manchester, United Kingdom
| | - G Dotti
- Lineberger Comprehensive Cancer Center and Department of Microbiology and Immunology, University of North Carolina, Chapel Hill, NC, United States
| | - M Massaia
- Laboratorio di Immunologia dei Tumori del Sangue, Centro Interdipartimentale di Ricerca in Biologia Molecolare, Università degli Studi di Torino, Turin, Italy; SC Ematologia, AO S. Croce e Carle, Cuneo, Italy
| | - G Pruneri
- Department of Pathology and Laboratory Medicine, Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, Italy
| | - A Anichini
- Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - O Fortunato
- Tumor Genomics Unit, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - F De Braud
- Medical Oncology Unit, Department of Medical Oncology and Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - M Del Vecchio
- Immunotherapy and Innovative Therapeutics Unit, Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; Unit of Melanoma Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - M Di Nicola
- Immunotherapy and Innovative Therapeutics Unit, Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; Medical Oncology Unit, Department of Medical Oncology and Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
| |
Collapse
|
24
|
Falasca K, Reale M, Di Nicola M, Ucciferri C, Zecca IA, Santilli F, Pontolillo M, Liani R, D'Angelo C, Costantini E, Vecchiet J. Circulating CD40 ligand, Dickkopf-1 and P-selectin in HIV-infected patients. HIV Med 2019; 20:681-690. [PMID: 31424619 DOI: 10.1111/hiv.12789] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 07/04/2019] [Indexed: 11/29/2022]
Abstract
OBJECTIVES The aim of this study was to evaluate the circulating levels of CD40 ligand (CD40 L), Dickkopf-1 (DKK-1) and P-selectin, their relationships and their contributions to cardiovascular risk in subjects with HIV infection. METHODS The study population included 80 HIV-infected patients, 14 (17.5%) of whom had diabetes mellitus (DM) and 32 (40.0%) of whom had arterial hypertension (AH). The HIV-infected patients were compared with a control group with similar demographic and clinical features. CD40L, DKK-1 and P-selectin levels were measured using an enzyme-linked immunosorbent assay. RESULTS The HIV-infected patients showed higher levels of all the cardiovascular disease (CVD) markers. Both serum CD40L and DKK-1 were significantly higher in HIV-infected patients than in the HIV-negative controls (P < 0.001), while soluble P-selectin showed no significant between-group difference (P = 0.133), reflecting the role of HIV infection in CVD. In the HIV-infected group, patients with DM showed lower levels of CD40L and DKK-1 in comparison with the nondiabetic patients and patients with AH (P < 0.05, with Bonferroni correction). In contrast, patients with AH showed higher levels of CD40L and DKK-1 in comparison to patients without DM or AH (P < 0.05, with Bonferroni correction). Patients with AH showed higher levels of CD40L and DKK-1 than patients with DM (P < 0.05, with Bonferroni correction). CONCLUSIONS In this study, we found that HIV-infected patients displayed significantly higher circulating levels of both CD40L and DKK-1, which were linearly and directly correlated, when compared to HIV-negative patients. The presence of diabetes was associated with lower levels of both CD40L and DKK-1, whereas the presence of hypertension was associated with higher levels of CD40L.
Collapse
Affiliation(s)
- K Falasca
- Clinic of Infectious Diseases, Department of Medicine and Science of Aging, University 'G. d'Annunzio' Chieti-Pescara, Chieti, Italy
| | - M Reale
- Unit of Immunodiagnostic and Molecular Pathology, Department of Medical, Oral and Biotechnological Sciences, University 'G. d'Annunzio' Chieti-Pescara, Chieti, Italy
| | - M Di Nicola
- Laboratory of Biostatistics, Department of Medical, Oral and Biotechnological Sciences, University 'G. d'Annunzio' Chieti-Pescara, Chieti, Italy
| | - C Ucciferri
- Clinic of Infectious Diseases, Department of Medicine and Science of Aging, University 'G. d'Annunzio' Chieti-Pescara, Chieti, Italy.,Department of Medicine and Health Sciences, University of Molise, Campobasso, Italy
| | - I A Zecca
- Division of Hygene, Epidemiology and Public Health, Department of Medicine and Science of Aging, University 'G. d'Annunzio' Chieti-Pescara, Chieti, Italy
| | - F Santilli
- Department of Medicine and Aging, Center of Aging Science and Translational Medicine (CESI-Met), University 'G. d'Annunzio' Chieti-Pescara, Chieti, Italy
| | - M Pontolillo
- Clinic of Infectious Diseases, Department of Medicine and Science of Aging, University 'G. d'Annunzio' Chieti-Pescara, Chieti, Italy
| | - R Liani
- Department of Medicine and Aging, Center of Aging Science and Translational Medicine (CESI-Met), University 'G. d'Annunzio' Chieti-Pescara, Chieti, Italy
| | - C D'Angelo
- Unit of Immunodiagnostic and Molecular Pathology, Department of Medical, Oral and Biotechnological Sciences, University 'G. d'Annunzio' Chieti-Pescara, Chieti, Italy
| | - E Costantini
- Unit of Immunodiagnostic and Molecular Pathology, Department of Medical, Oral and Biotechnological Sciences, University 'G. d'Annunzio' Chieti-Pescara, Chieti, Italy
| | - J Vecchiet
- Clinic of Infectious Diseases, Department of Medicine and Science of Aging, University 'G. d'Annunzio' Chieti-Pescara, Chieti, Italy
| |
Collapse
|
25
|
De Santis MC, La Rocca E, Meneghini E, Bregni G, Di Lorenzo G, Galli G, Di Nicola M, Folli S, Gennaro M, Pruneri G, Paolini B, Daidone MG, De Braud F, Apolone G, Sant M, Di Cosimo S. Axillary nodal involvement by primary tumor features in early breast cancer: an analysis of 2600 patients. Clin Transl Oncol 2019; 22:786-792. [PMID: 31372896 DOI: 10.1007/s12094-019-02188-7] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/05/2019] [Accepted: 07/17/2019] [Indexed: 10/26/2022]
Abstract
BACKGROUND Primary tumor characteristics, which are readily available to all clinicians, may aid in selecting the optimal adjuvant therapy for patients with breast cancer (BC). Herein, we investigated the relationship between tumor size, hormone receptor and HER2 status, Ki67 and age with axillary lymph node metastases (ALNM) in early-BC patients. METHODS We analyzed data on consecutive 2600 early-BC cases collected in the registry of Fondazione IRCC Istituto Nazionale dei Tumori, Milano, Italy. Correlation between Ki67 and primary tumor size (T-size) was calculated by Spearman's rank correlation coefficient. Association of ALNM with Ki67 and other tumor characteristics was investigated by logistic regression. Adjusted odds ratios (ORs) with 95% confidence intervals (95% CIs) were estimated in all cases, and separately analyzed according to age, T-size and BC subtype. RESULTS Large tumor size strongly associated to ALNM, with an adjusted odds ratio (OR) for each 5-mm increase of 1.32 (95% CI 1.24-1.41), except for triple-negative BC (TNBC) cases. In tumors =10 mm, without lymphovascular invasion, representing the strongest predictor of ALNM (OR 6.09, 95% CI 4.93-7.53), Ki67 resulted particularly informative, with a fourfold increased odds of ALNM for values > 30%. CONCLUSIONS These results raise the question whether axillary node status is redundant in cases with exceptionally good features, i.e., small tumors with low Ki67, or in those candidate to adjuvant systemic treatment/radiotherapy anyway including TNBC, and support the incorporation of primary BC tumor characteristics as stratification factors in ongoing trials aiming at de-escalating axillary surgical procedures.
Collapse
Affiliation(s)
- M C De Santis
- Radiotherapy Unit 1, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - E La Rocca
- Radiotherapy Unit 1, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.,School of Medicine, Università degli Studi di Milan, Milan, Italy
| | - E Meneghini
- Analytical Epidemiology and Health Impact Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - G Bregni
- Medical Oncology, Ospedale Policlinico S. Martino IRCCS, Genova, Italy
| | - G Di Lorenzo
- Radiotherapy Unit 1, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.,School of Medicine, Università degli Studi di Milan, Milan, Italy
| | - G Galli
- School of Medicine, Università degli Studi di Milan, Milan, Italy.,Division of Medical Oncology 1, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - M Di Nicola
- Division of Medical Oncology 1, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - S Folli
- Breast Surgery Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - M Gennaro
- Breast Surgery Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - G Pruneri
- School of Medicine, Università degli Studi di Milan, Milan, Italy.,Department of Pathology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - B Paolini
- Department of Pathology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - M G Daidone
- Biomarker Unit, Department of Applied Research and Technological Development, Fondazione IRCCS Istituto Nazionale dei Tumori, Via G Amadeo 42, 20133, Milan, Italy
| | - F De Braud
- School of Medicine, Università degli Studi di Milan, Milan, Italy.,Scientific Directorate, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - G Apolone
- Scientific Directorate, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - M Sant
- Analytical Epidemiology and Health Impact Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - S Di Cosimo
- Biomarker Unit, Department of Applied Research and Technological Development, Fondazione IRCCS Istituto Nazionale dei Tumori, Via G Amadeo 42, 20133, Milan, Italy.
| |
Collapse
|
26
|
Caravatta L, Cellini F, Simoni N, Rosa C, Niespolo R, Lupattelli M, Picardi V, Macchia G, Sainato A, Mantello G, Dionisi F, Rosetto M, Fusco V, Navarria F, De Paoli A, Guido A, Vecchi C, Basilico R, Cianci R, Pizzi AD, Di Nicola M, Mattiucci G, Valentini V, Morganti A, Genovesi D. PO-0809 Gross Tumor Volume delineation in pancreatic cancer using MRI: final results of a multicenter study. Radiother Oncol 2019. [DOI: 10.1016/s0167-8140(19)31229-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
27
|
Gasparini L, Rosa C, Di Biase S, Di Carlo C, Allajbej A, Patani F, Fasciolo D, Porreca A, Di Nicola M, Caravatta L, Genovesi D. EP-1647 Neoadjuvant chemoradiotherapy in elderly rectal cancer patients in a mono-institutional experience. Radiother Oncol 2019. [DOI: 10.1016/s0167-8140(19)32067-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
28
|
Di Nicola M, Volpari T, Fucà G, Romero Cordoba S, De Santis F, Rondinone O, Faraci S, Ferris F, Puricelli C, Castagnoli L, Marullo R, Cerchietti L, Pupa S. Abstract P1-07-02: Withdrawn. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p1-07-02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
This abstract was withdrawn by the authors.
Citation Format: Di Nicola M, Volpari T, Fucà G, Romero Cordoba S, De Santis F, Rondinone O, Faraci S, Ferris F, Puricelli C, Castagnoli L, Marullo R, Cerchietti L, Pupa S. Withdrawn [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P1-07-02.
Collapse
Affiliation(s)
- M Di Nicola
- Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy; Cornell University, New York
| | - T Volpari
- Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy; Cornell University, New York
| | - G Fucà
- Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy; Cornell University, New York
| | - S Romero Cordoba
- Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy; Cornell University, New York
| | - F De Santis
- Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy; Cornell University, New York
| | - O Rondinone
- Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy; Cornell University, New York
| | - S Faraci
- Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy; Cornell University, New York
| | - F Ferris
- Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy; Cornell University, New York
| | - C Puricelli
- Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy; Cornell University, New York
| | - L Castagnoli
- Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy; Cornell University, New York
| | - R Marullo
- Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy; Cornell University, New York
| | - L Cerchietti
- Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy; Cornell University, New York
| | - S Pupa
- Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy; Cornell University, New York
| |
Collapse
|
29
|
De Santis F, Del Vecchio M, Castagnoli L, De Braud F, Di Cosimo S, Franceschini D, Fucà G, Hiscott J, Malmberg KJ, McGranahan N, Pietrantonio F, Rivoltini L, Sangaletti S, Tagliabue E, Tripodo C, Vernieri C, Zitvogel L, Pupa SM, Di Nicola M. Innovative therapy, monoclonal antibodies, and beyond: Highlights from the eighth annual meeting. Cytokine Growth Factor Rev 2018; 44:1-10. [PMID: 30393044 DOI: 10.1016/j.cytogfr.2018.10.005] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
The eighth annual conference of "Innovative therapy, monoclonal antibodies, and beyond" was held in Milan on Jan. 26, 2018, and hosted by Fondazione IRCCS-Istituto Nazionale dei Tumori (Fondazione IRCCS INT). The conference was divided into two main scientific sessions, of i) pre-clinical assays and novel biotargets, and ii) clinical translation, as well as a third session of presentations from young investigators, which focused on recent achievements within Fondazione IRCCS INT on immunotherapy and targeted therapies. Presentations in the first session addressed the issue of cancer immunotherapy activity with respect to tumor heterogeneity, with key topics addressing: 1) tumor heterogeneity and targeted therapy, with the definition of the evolutionary Index as an indicator of tumor heterogeneity in both space and time; 2) the analysis of cancer evolution, with the introduction of the TRACERx Consortium-a multi-million pound UK research project focused on non-small cell lung cancer (NSCLC); 3) the use of anti-estrogen agents to boost immune recognition of breast cancer cells; and 4) the high degree of functional plasticity within the NK cell repertoire, including the expansion of adaptive NK cells following viral challenges. The second session addressed: 1) the effectiveness of radiotherapy to enhance the proportion of patients responsive to immune-checkpoint blockers (ICBs); 2) the use of MDSC scores in selecting melanoma patients with high probability to be responsive to ICBs; and 3) the relevance of the gut microbiome as a predictive factor, and the potential of its perturbation in increasing the immune response rate to ICBs. Overall, a picture emerged of tumor heterogeneity as the main limitation that impairs the effectiveness of anti-cancer therapies. Thus, the choice of a specific therapy based on reproducible and selective predictive biomarkers is an urgent unmet clinical need that should be addressed in order to increase the proportion of long-term responding patients and to improve the sustainability of novel drugs.
Collapse
Affiliation(s)
- F De Santis
- Immunotherapy and Innovative Therapeutics Unit, Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - M Del Vecchio
- Immunotherapy and Innovative Therapeutics Unit, Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; Unit of Melanoma Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - L Castagnoli
- Molecular Targeting Unit, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - F De Braud
- Medical Oncology Unit, Dept of Medical Oncology and Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - S Di Cosimo
- Department of Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - D Franceschini
- Radiotherapy and Radiosurgery, Humanitas Clinical and Research Center, Via Manzoni 56 20089 Rozzano (Milano) Italy
| | - G Fucà
- Medical Oncology Unit, Dept of Medical Oncology and Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - J Hiscott
- Laboratorio Pasteur, Istituto Pasteur-Fondazione Cenci-Bolognetti, 00161 Rome, Italy
| | - K J Malmberg
- Center for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden; Department. of Cellular Therapy and Allogeneic Stem Cell Transplantation, Karolinska University Hospital, Stockholm, Sweden; Institute for Cancer Research, Oslo University Hospital, Oslo, Norway; The KG Jebsen Centre for Cancer Immunotherapy, University of Oslo, Oslo, Norway
| | - N McGranahan
- Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK
| | - F Pietrantonio
- Medical Oncology Unit, Dept of Medical Oncology and Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy
| | - L Rivoltini
- Unit of Immunotherapy of Human Tumors, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - S Sangaletti
- Molecular Immunology Unit, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - E Tagliabue
- Molecular Targeting Unit, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - C Tripodo
- Tumor Immunology Unit, Department of Health Science, Human Pathology Section, University of Palermo School of Medicine, Palermo, Italy
| | - C Vernieri
- Thoracic Oncology, Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; Fondazione Istituto FIRC di Oncologia Molecolare (IFOM), Milan, Italy
| | - L Zitvogel
- Gustave Roussy Cancer Campus (GRCC), Villejuif, France; Institut National de la Santé Et de la Recherche Medicale (INSERM), Villejuif, France; Univ. Paris-Sud, Université Paris-Saclay, Gustave Roussy, Villejuif, France; Center of Clinical Investigations in Biotherapies of Cancer (CICBT), Villejuif, France
| | - S M Pupa
- Molecular Targeting Unit, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - M Di Nicola
- Immunotherapy and Innovative Therapeutics Unit, Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; Medical Oncology Unit, Dept of Medical Oncology and Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
| |
Collapse
|
30
|
Cona M, Lecchi M, Damian S, Del Vecchio M, Cimminiello C, Cresta S, Duca M, Necchi A, Signorelli D, Poggi M, Raggi D, Ratta R, Verderio P, de Braud F, Di Nicola M. Combination of baseline LDH, performance status and age to identify solid tumor patients with higher probability of response to anti-PD1 and PDL1 monoclonal antibodies. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy269.109] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
31
|
Paz-Ares L, Kim T, Vicente D, Felip E, Lee D, Lee K, Lin CC, Oncala M, Di Nicola M, Alvarez R, Dussault I, Helwig C, Ojalvo L, Gulley J, Cho B. Updated results of M7824 (MSB0011359C): A bifunctional fusion protein targeting TGF-β and PD-L1, in second-line (2L) NSCLC. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy292.085] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
32
|
Farè E, Sdao S, Damian S, Cresta S, Del Vecchio M, Di Bartolomeo M, Di Guardo L, Duca M, Indini A, Necchi A, Niger M, Prisciandaro M, Procopio G, Raggi D, Verzoni E, Pruneri G, Di Nicola M, de Braud F. Hyperprogression during immuno-checkpoint inhibitors (ICIs): A clinically significant problem? Ann Oncol 2018. [DOI: 10.1093/annonc/mdy288.083] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
33
|
Chiti A, Di Nicola M, Spinelli A, Siena S, Bregni M, Savelli G, Gianni MA, Bombardieri E. A Case of Metastatic Axillary Lymph Nodes Involvement from Unknown Primary Cancer: Clinical Usefulness of [99mTc]-Sestamibi. Tumori 2018; 84:612-3. [PMID: 9862528 DOI: 10.1177/030089169808400521] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Affiliation(s)
- A Chiti
- Nuclear Medicine Department, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milano, Italy
| | | | | | | | | | | | | | | |
Collapse
|
34
|
Ravagnani F, Notti P, Siena S, Bregni M, Zorzino L, Di Nicola M, Belli N, Gianni A, Pellegris G. Clinical Application of Growth Factors for Collection of Circulating Hematopoietic Progenitors in Breast Cancer Patients Treated with Highdose Cyclophosphamide. Int J Artif Organs 2018. [DOI: 10.1177/039139889301605s07] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Seventy-seven (68 operable breast cancer with > 9 metastatic axillary nodes and 9 inflammatory breast cancer) entered this study. During hematopoietic recovery after cancer therapy with highdose cyclophosphamide (7 g/m2; HD-CTX) circulating hematopoietic progenitors were collected by leukapheresis (LK) in all patients and then cryopreserved for autologous transplantation. Following HD-CTX, 70 patients were treated with hematopoietic growth factor(s) for 14 days: 38 with rhGM-CSF (group a), 16 with rhlL-3 (group b), 11 with sequential rhlL-3 and rhGM-CSF (group c), 5 with sequential rhlL-3 and rhG-CSF (group d). Seven control patients (group e) did not receive any growth factor. Leukaphereses, carried out over 2-4 consecutive days per patient, were started earlier in group c and in group d patients (mean day: +12 after HD-CTX). The sequential administration of rhIL-3 and rhG-CSF (group d) resulted in clearly higher yield of CFU-GM and CD34+ cells per leukapheresis (65.9x104/Kg versus 20.9x106/Kg, respectively) if compared with other groups of treatment.
Collapse
Affiliation(s)
- F. Ravagnani
- Division of Immunohematology, National Tumor Institute, Milano - Italy
| | - P. Notti
- Division of Immunohematology, National Tumor Institute, Milano - Italy
| | - S. Siena
- Cristina Gandini Transplantation Unit, Division of Medical Oncology, National Tumor Institute, Milano - Italy
| | - M. Bregni
- Cristina Gandini Transplantation Unit, Division of Medical Oncology, National Tumor Institute, Milano - Italy
| | - L. Zorzino
- Division of Immunohematology, National Tumor Institute, Milano - Italy
| | - M. Di Nicola
- Cristina Gandini Transplantation Unit, Division of Medical Oncology, National Tumor Institute, Milano - Italy
| | - N. Belli
- Cristina Gandini Transplantation Unit, Division of Medical Oncology, National Tumor Institute, Milano - Italy
| | - A.M. Gianni
- Cristina Gandini Transplantation Unit, Division of Medical Oncology, National Tumor Institute, Milano - Italy
| | - G. Pellegris
- Division of Immunohematology, National Tumor Institute, Milano - Italy
| |
Collapse
|
35
|
Di Nicola M, Siena S, Bregni M, Peccatori F, Magni M, Ravagnani F, Zorzino L, Bonadonna G, Gianni A. Quantization of CD34+ Peripheral Blood Hematopoietic Progenitors for Autografting in Cancer Patients. Int J Artif Organs 2018. [DOI: 10.1177/039139889301605s15] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
After myeloablative regimens, combined reinfusion of peripheral blood hematopoietic circulating progenitor cells (CPC) and bone marrow, yields a very rapid hematopoietic recovery. Therefore, based on the knowledge that CPC express the CD34 and CD33 differentiation antigen, we have developed a direct immunofluorescence flow cytometry assay to detect the peak of CPC in the peripheral blood of patients treated with high dose chemotherapy and growth factors. This assay, compared to CFU-GM assay, has the following advantages: 1) easy to do 2) standardized method 3) real time information on CPC number. This work illustrates the practical aspects of this assay and substantiate the widespread use of the CD34/33 flow cytometry assay to guide harvesting of circulating hematopoietic progenitors for autologous transplantation.
Collapse
Affiliation(s)
- M. Di Nicola
- Cristina Gandini Unit, Division of Medical Oncology, Milano
| | - S. Siena
- Cristina Gandini Unit, Division of Medical Oncology, Milano
| | - M. Bregni
- Cristina Gandini Unit, Division of Medical Oncology, Milano
| | - F. Peccatori
- Cristina Gandini Unit, Division of Medical Oncology, Milano
| | - M. Magni
- Cristina Gandini Unit, Division of Medical Oncology, Milano
| | - F. Ravagnani
- Division of Immunohematology, Istituto Nazionale Tumori, Milano
| | - L. Zorzino
- Division of Immunohematology, Istituto Nazionale Tumori, Milano
| | - G. Bonadonna
- Cristina Gandini Unit, Division of Medical Oncology, Milano
| | - A.M. Gianni
- Cristina Gandini Unit, Division of Medical Oncology, Milano
- Institute of Medical Sciences, Università degli Studi, Milano - Italy
| |
Collapse
|
36
|
Rosa C, Di Tommaso M, Caravatta L, Taraborrelli M, Augurio A, Di Biase S, Zecca I, Di Nicola M, Genovesi D. EP-1491: Neoadjuvant chemoradiotherapy in rectal cancer patients in a 15-year single institutional experience. Radiother Oncol 2018. [DOI: 10.1016/s0167-8140(18)31800-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
37
|
Rosa C, Caravatta L, Di Tommaso M, Cianci R, Delli Pizzi A, Vinciguerra A, Zecca I, Di Nicola M, Genovesi D. EP-1493: T2 and Diffusion weighted MRI for GTV delineation in rectal cancer: agreement between volumes. Radiother Oncol 2018. [DOI: 10.1016/s0167-8140(18)31802-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
38
|
de Braud F, Di Nicola M, Damian S, Cresta S, Duca M, Indini A, Di Bartolomeo M, Galli G, Farè E, Verzoni E. Is “hyper-progression” a relevant clinical item for patient with solid tumours candidate to check-point inhibitor treatment? Ann Oncol 2018. [DOI: 10.1093/annonc/mdy046.018] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
39
|
Di Nicola M, Apetoh L, Bellone M, Colombo MP, Dotti G, Ferrone S, Muscolini M, Hiscott J, Anichini A, Pupa SM, Braud FD, Del Vecchio M. Innovative Therapy, Monoclonal Antibodies and Beyond. Cytokine Growth Factor Rev 2017; 38:1-9. [PMID: 29029813 DOI: 10.1016/j.cytogfr.2017.10.002] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/25/2017] [Accepted: 10/02/2017] [Indexed: 02/07/2023]
Abstract
The seventh Edition of "Innovative Therapy, Monoclonal Antibodies and Beyond" Meeting took place in Milan, Italy, on January 27, 2017. The two sessions of the meeting were focused on: 1) Preclinical assays and novel biotargets; and 2) monoclonal antibodies, cell therapies and targeted molecules. Between these two sessions, a lecture entitled "HLA-antigens modulation and response to immune checkpoint inhibitor immunotherapy" was also presented. Despite the impressive successes in cancer immunotherapy in recent years, the response to immune based interventions occurs only in a minority of patients (∼20%). Several basic and translational mechanisms of resistance to immune checkpoint blockers (ICBs) were discussed during the meeting: 1. the impact of tumor microenvironment on the activity of immune system; 2. strategies to inhibit the cross-talk between extracellular matrix and myeloid-derived suppressor cells (MDSC) in the preclinical setting; 3. microRNA expression as a biomarker and as a target of therapy in non-small cell lung cancer (NSCLC); 4. the significance of complement activation pathways in response to immune checkpoint inhibitors; 5. the immunosuppressive activity of the microbiota by inducing IL-17 producing cells; and 6. modulation of HLA antigens as possible markers of response to ICB therapy. In order to overcome the deficiency in active anti-tumor T cells, several clinically applicable combination strategies were also discussed: 1. strategies to enhance the anticancer effects of immunogenic cell death inducing-chemotherapy; 2. the use of CAR T-cells in solid tumors; 3. the use of combination strategies involving oncolytic viruses and ICBs; 4. combinations of new ICBs with anti-PD-1/CTLA-4 therapy; and 4. combinations of targeted therapies and ICBs in melanoma. Overall, this conference emphasized the many novel strategies that are being investigated to improve the overall patient response to cancer immunotherapy. Optimization of biomarkers to accurately select patients who will respond to immunotherapy, coupled with combination strategies to improve long term patient survival remain critical challenges in the immuno-oncology field.
Collapse
Affiliation(s)
- M Di Nicola
- Unit of Immunotherapy and Anticancer Innovative Therapeutics, Milan, Italy; Medical Oncology Unit, Dept of Medical Oncology and Hematology, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy.
| | - L Apetoh
- INSERM, U1231, Dijon, France; 4Faculté de Médecine, Université de Bourgogne Franche Comté, Dijon, France
| | - M Bellone
- Cellular Immunology Unit, Division of Immunology, Transplantation and Infectious Diseases, IRCSS San Raffaele Scientific Institute, Milan, Italy
| | - M P Colombo
- Centre Georges François Leclerc, Dijon, France
| | - G Dotti
- Department of Microbiology and Immunology, University of North Carolina, Chapel Hill, NC, USA
| | - S Ferrone
- Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
| | - M Muscolini
- Laboratorio Pasteur, Istituto Pasteur-Fondazione Cenci Bolognetti, 00161 Rome, Italy
| | - J Hiscott
- Laboratorio Pasteur, Istituto Pasteur-Fondazione Cenci Bolognetti, 00161 Rome, Italy
| | - A Anichini
- Human Tumor Immunobiology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - S M Pupa
- Molecular Targeting Unit, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - F de Braud
- Medical Oncology Unit, Dept of Medical Oncology and Hematology, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy
| | - M Del Vecchio
- Medical Oncology Unit, Dept of Medical Oncology and Hematology, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy; Unit of Melanoma Medical Oncology, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy.
| |
Collapse
|
40
|
Di Carlo C, Nuzzo M, Ursini L, Trignani M, Caravatta L, Di Girolamo G, Di Nicola M, Genovesi D. EP-1178: Breast radiotherapy without nodal irradiation in pT1-2 pN0-1 stage: prognostic factors and outcomes. Radiother Oncol 2017. [DOI: 10.1016/s0167-8140(17)31614-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
41
|
Moccia L, Pettorruso M, De Risio L, De Crescenzo F, Di Nuzzo L, Conte E, Leone B, Ferri V, Martinotti G, Di Nicola M, Janiri L. The neural basis of cognitive control in gambling disorder: A systematic review of fMRI studies. Eur Psychiatry 2017. [DOI: 10.1016/j.eurpsy.2017.01.1748] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
Abstract
IntroductionDecreased cognitive control over the urge to be involved in gambling activities is a core feature of gambling disorder (GD). Cognitive control can be conceptualized as the sum of high-order cognitive faculties interacting in the achievement of goal-oriented behaviors. As such, cognitive control can be differentiated into several cognitive sub-processes, such as response inhibition, conflict monitoring, decision-making and cognitive flexibility, all of which prove to be pivotal in GD clinical phenomenology.ObjectivesOver the past few years, several studies and reviews have indicated a lack of cognitive control in GD through self-report questionnaires and neurocognitive tasks. Conversely, there are only a limited number of neuroimaging studies, which investigate the neural mechanisms underlying diminished cognitive control in GD.AimsThis research aims to systematically review functional magnetic resonance imaging (fMRI) studies that target cognitive control in GD.MethodsA literature search was conducted in order to find appropriate published articles on fMRI studies in GD.ResultsFourteen fMRI studies were included. Depending on which neurocognitive task was employed, the studies were divided into five different sections: conflict monitoring, response inhibition, delay discounting, cognitive flexibility and decision-making.ConclusionsImpaired activity in prefrontal cortex may account for decreased cognitive control in GD, contributing to the progressive loss of control over gambling behaviors. However, the way in which cognitive control interacts with affective and motivational processes in GD is still matter of investigation. Among prefrontal areas, orbitofrontal cortex has been indicated as a possible nexus for sensory integration, value-based decision-making and emotional processing, thus contributing to both motivational and affective aspects of cognitive control.Disclosure of interestThe authors have not supplied their declaration of competing interest.
Collapse
|
42
|
Mazza M, Marano G, Traversi G, Di Nicola M, Catalano V, Janiri L. The complex interplay of Depression, Inflammation and Omega-3: state of the art and progresses in research. Clin Ter 2016; 166:e242-7. [PMID: 26152637 DOI: 10.7417/ct.2015.1859] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
Many epidemiological and preclinical studies have proven the potential benefit and critical role of omega-3 PUFAs in the development and management of depressive disorders. Depression may be the consequence of a complex interplay between cell-mediated-immune activation and inflammation evolving in neuroprogression. Associations between n-3 PUFAs, inflammation, oxidative stress and the risk of depression have been demonstrated and clinical and animal supplementation studies have shown the potential of PUFAs to decrease neurodegeneration and inflammation. Future research should focus on the dynamic interactions between the different cell signaling networks and oxidative and nitrosative stress pathways that cause depression.
Collapse
Affiliation(s)
- M Mazza
- Department of Neurosciences, Università Cattolica del Sacro Cuore, Rome, Italy
| | - G Marano
- Department of Neurosciences, Università Cattolica del Sacro Cuore, Rome, Italy
| | - G Traversi
- Department of Neurosciences, Università Cattolica del Sacro Cuore, Rome, Italy
| | - M Di Nicola
- Department of Neurosciences, Università Cattolica del Sacro Cuore, Rome, Italy
| | - V Catalano
- Department of Neurosciences, Università Cattolica del Sacro Cuore, Rome, Italy
| | - L Janiri
- Department of Neurosciences, Università Cattolica del Sacro Cuore, Rome, Italy
| |
Collapse
|
43
|
Gigliotti C, Vecchio AD, Perna L, Fiorino C, Modorati G, Nicola MD, Mortini P, Picozzi P, Franzin A, Bolognesi A, Calandrino R. Dose-volume predictors of radio-induced complications after radiosurgery for uveal melanoma. Phys Med 2016. [DOI: 10.1016/j.ejmp.2016.07.108] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
44
|
Cefalogli C, Trignani M, Ursini L, D'Aviero A, Di Tommaso M, Di Santo S, Pamio A, Di Nicola M, Genovesi D. EP-1165: Impact of nodal status on clinical outcome of breast cancer patients: a monoinstitutional experience. Radiother Oncol 2016. [DOI: 10.1016/s0167-8140(16)32415-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
45
|
Gigliotti C, Di Nicola M, Perna L, Fiorino C, Modorati G, Mortini P, Franzin A, Bolognesi A, Del Vecchio A, Calandrino R. PO-0762: Dose-volume predictors of radio-induced effects after SRS for uveal melanoma. Radiother Oncol 2016. [DOI: 10.1016/s0167-8140(16)32012-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
46
|
Signorelli D, Cona M, Lo Russo G, Proto C, Vitali M, Macerelli M, Agustoni F, Indini A, Platania M, Zilembo N, Garassino M, Di Guardo L, Del Vecchio M, Magni M, Sinno V, Seregni E, Di Nicola M, de Braud F. Disthyroidism during immune checkpoints inhibitors treatment: toxicity or something more? Ann Oncol 2015. [DOI: 10.1093/annonc/mdv348.06] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
47
|
Donatelli F, Nafi M, Di Nicola M, Macchitelli V, Mirabile C, Lorini L, Carli F. Twenty-four hour hyperinsulinemic-euglycemic clamp improves postoperative nitrogen balance only in low insulin sensitivity patients following cardiac surgery. Acta Anaesthesiol Scand 2015; 59:710-22. [PMID: 25867209 DOI: 10.1111/aas.12526] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/09/2014] [Revised: 02/06/2015] [Accepted: 02/27/2015] [Indexed: 12/24/2022]
Abstract
BACKGROUND Critically ill patients often suffer from a protein catabolic state. The aim of this study was to demonstrate that nitrogen balance (NB) in cardiac patients admitted to the intensive care unit (ICU) is related to their insulin sensitivity level and that supraphysiologic doses of insulin can restore anabolism. MATERIALS AND METHODS Twenty-eight patients that were admitted to ICU in enteral and/or parenteral nutrition have been enrolled in this study. All patients received a standard nutrition protocol for at least 3 days before starting the study. These patients received either enteral or parenteral nutrition based on 1.4 kcal/kg/h and 1.1 g/kg/24 h of proteins. Participants were studied for three 24 h periods (P1 , P2 , and P3 ). Twenty-four hour NB was calculated from urinary urea nitrogen excretion, fixed protein and energy intake during each of the three periods (P1 , P2 , and P3 ). Simultaneous to P2, a 24 h hyperinsulinemic-euglycemic clamp (HEC) was performed to determine patients' insulin sensitivity (IS) or insulin resistance (IR), as well as the impact of high doses of insulin on NB. RESULTS Nitrogen balance remained consistently positive in the IS group regardless of the clamp. In IR patients, NB was negative before the clamp and became positive during P2 and P3 . Insulin sensitivity improved during the HEC in IR patients (P < 0.001). CONCLUSIONS A negative NB was found only in insulin resistant patients admitted to the ICU for more than 7 days. A 24-h period HEC improved NB in these patients.
Collapse
Affiliation(s)
- F. Donatelli
- Ospedali Riuniti di Bergamo; Bergamo Italy
- McGill University Health Centre; Montreal Quebec Canada
| | - M. Nafi
- Università degli Studi di Milano; School of Anesthesia and Intensive Care; Milano Italy
| | - M. Di Nicola
- Università degli Studi “G. D'Annunzio” di Chieti-Pescara; Chieti Italy
| | | | | | - L. Lorini
- Ospedali Riuniti di Bergamo; Bergamo Italy
| | - F. Carli
- McGill University Health Centre; Montreal Quebec Canada
| |
Collapse
|
48
|
Auriemma M, Di Nicola M, Varrati S, Carbone A, Pamio A, Capo A, Tracanna M, Castigliego AP, Tiboni GM, Amerio P. Mole modifications following controlled ovarian stimulation for assisted reproduction technologies. J Eur Acad Dermatol Venereol 2015; 29:1913-7. [PMID: 25879151 DOI: 10.1111/jdv.13065] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/15/2014] [Accepted: 02/04/2015] [Indexed: 11/27/2022]
Abstract
BACKGROUND The role of estrogens on moles biology remains undefined although estrogenic receptors have been found on melanocytes. It has been postulated that supraphysiological estrogen levels could promote the progression of moles to melanoma. Women undergoing controlled ovarian stimulation (COS) for assisted reproductive technologies (ART) are exposed to high levels of estrogens, produced by the ovary in response to exogenous gonadotropin administration. The aim of this study is to assess whether COS for ART may have an impact on mole structure and/or characteristics. METHODS Women undergoing to ART for various infertility conditions were included in the study. Personal and clinical data were collected. Dermatoscopic features and scores (total dermoscopy score--TDS) were statistically compared before COS and after a 6-month follow-up period. Statistical correlation was performed between estradiol, FSH blood levels and relative variation in moles dimensions. RESULTS A total of 46 patients were included in the study. One hundred and seventy-five melanocytic lesions from 31 patients were evaluated at both time points. Although statistically significant differences were found in mole dimension and TDS between the two time points, these differences had no relevance in the clinical setting not suggesting the need for mole excision. Moreover, the only statistically significant correlation with estradiol blood concentration on hCG administration day was found with one-axis dimensional variation. CONCLUSIONS To our knowledge this is the first work to evaluate the effect of COS on moles. The obtained results do not support a causal relation between the supraphysiological hormone levels stimulation and worsening of clinical and dermoscopical features of moles. Further study is needed to clarify whether estrogens plays a role in melanoma.
Collapse
Affiliation(s)
- M Auriemma
- Department of Medicine and Aging Science and Dermatologic Clinic, University "G. d'Annunzio", Chieti-Pescara, Chieti, Italy
| | - M Di Nicola
- Department of Experimental and Clinical Sciences, University "G. d'Annunzio", Chieti-Pescara, Chieti, Italy
| | - S Varrati
- Department of Medicine and Aging Science and Dermatologic Clinic, University "G. d'Annunzio", Chieti-Pescara, Chieti, Italy
| | - A Carbone
- L'Immacolata Hospital, Catholic University of the Sacred Heart, Celano (AQ), Italy
| | - A Pamio
- Department of Medicine and Aging Science, University "G. d'Annunzio", Chieti-Pescara, Chieti, Italy
| | - A Capo
- Department of Medicine and Aging Science and Dermatologic Clinic, University "G. d'Annunzio", Chieti-Pescara, Chieti, Italy
| | - M Tracanna
- Department of Medicine and Aging Science and Dermatologic Clinic, University "G. d'Annunzio", Chieti-Pescara, Chieti, Italy
| | - A P Castigliego
- Department of Medicine and Aging Science, University "G. d'Annunzio", Chieti-Pescara, Chieti, Italy
| | - G M Tiboni
- Department of Medicine and Aging Science, University "G. d'Annunzio", Chieti-Pescara, Chieti, Italy
| | - P Amerio
- Department of Medicine and Aging Science and Dermatologic Clinic, University "G. d'Annunzio", Chieti-Pescara, Chieti, Italy
| |
Collapse
|
49
|
Necchi A, Mariani L, Di Nicola M, Lo Vullo S, Nicolai N, Giannatempo P, Raggi D, Farè E, Magni M, Piva L, Matteucci P, Catanzaro M, Biasoni D, Torelli T, Stagni S, Bengala C, Barone C, Schiavetto I, Siena S, Carlo-Stella C, Pizzocaro G, Salvioni R, Gianni AM. High-dose sequential chemotherapy (HDS) versus PEB chemotherapy as first-line treatment of patients with poor prognosis germ-cell tumors: mature results of an Italian randomized phase II study. Ann Oncol 2015; 26:167-172. [PMID: 25344361 DOI: 10.1093/annonc/mdu485] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022] Open
Abstract
BACKGROUND In the late 1990s, the use of high-dose chemotherapy (HDCT) and stem-cell rescue held promise for patients with advanced and poor prognosis germ-cell tumors (GCT). We started a randomized phase II trial to assess the efficacy of sequential HDCT compared with cisplatin, etoposide, and bleomycin (PEB). PATIENTS AND METHODS Patients were randomly assigned to receive four cycles of PEB every 3 weeks or two cycles of PEB followed by a high-dose sequence (HDS) comprising HD-cyclophosphamide (7.0 g/m(2)), 2 courses of cisplatin and HD-etoposide (2.4 g/m(2)) with stem-cell support, and a single course of HD-carboplatin [area under the curve (AUC) 27 mg/ml × min] with autologous stem-cell transplant. Postchemotherapy surgery was planned on responding residual disease in both arms. The primary end point was progression-free survival (PFS). The study was designed to detect a 30% improvement of 5-year PFS (from 40% to 70%), with 80% power and two-sided α at 5%. RESULTS From December 1996 to March 2007, 85 patients were randomized: 43 in PEB and 42 in HDS arm. Median follow-up was 114.2 months [interquartile range (IQR): 87.7-165.8]. Complete or partial response with normal markers (PRm-) were obtained in 28 (65.1%) and 29 (69.1%) patients, respectively. Five-year PFS was 55.8% [95% confidence interval (CI) 42.8-72.8] and 54.8% (95% CI 41.6%-72.1%) in PEB and HDS arm, respectively (log-rank test P = 0.726). Five-year overall survival was 62.8% (95% CI 49.9-79.0) and 59.3% (95% CI 46.1-76.3). One toxic death (PEB arm) was recorded. CONCLUSIONS The study failed to meet the primary end point. Furthermore, survival estimates of conventional-dose chemotherapy higher than expected should be accounted for and will likely limit further improvements in the first-line setting. CLINICALTRIALS.GOV: NCT02161692.
Collapse
Affiliation(s)
| | - L Mariani
- Clinical Epidemiology and Trials Organization Unit
| | | | - S Lo Vullo
- Clinical Epidemiology and Trials Organization Unit
| | - N Nicolai
- Department of Surgery, Urology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan
| | | | - D Raggi
- Department of Medical Oncology
| | - E Farè
- Department of Medical Oncology
| | - M Magni
- Department of Medical Oncology
| | - L Piva
- Department of Surgery, Urology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan
| | | | - M Catanzaro
- Department of Surgery, Urology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan
| | - D Biasoni
- Department of Surgery, Urology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan
| | - T Torelli
- Department of Surgery, Urology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan
| | - S Stagni
- Department of Surgery, Urology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan
| | - C Bengala
- Department of Medical Oncology, Ospedale Misericordia, Grosseto
| | - C Barone
- Department of Medical Oncology, Oncologia Medica ASL TO5 Ospedale di Carmagnola, Turin
| | - I Schiavetto
- Niguarda Cancer Center, Ospedale Niguarda Ca' Granda, Milan
| | - S Siena
- Niguarda Cancer Center, Ospedale Niguarda Ca' Granda, Milan
| | - C Carlo-Stella
- Department of Oncology and Hematology, Humanitas Cancer Center, Humanitas Clinical and Research Center, Rozzano; Department of Medical Biotechnology and Translational Medicine
| | - G Pizzocaro
- Department of Surgery, Urology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan
| | - R Salvioni
- Department of Surgery, Urology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan
| | - A M Gianni
- Department of Medical Oncology; Department of Pathophysiology and Transplantation, University of Milano, Milan, Italy
| |
Collapse
|
50
|
Silvestri I, Testa F, Zappasodi R, Cairo CW, Zhang Y, Lupo B, Galli R, Di Nicola M, Venerando B, Tringali C. Sialidase NEU4 is involved in glioblastoma stem cell survival. Cell Death Dis 2014; 5:e1381. [PMID: 25144716 PMCID: PMC4454322 DOI: 10.1038/cddis.2014.349] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/15/2014] [Revised: 07/08/2014] [Accepted: 07/09/2014] [Indexed: 01/30/2023]
Abstract
The human sialidase, NEU4, has emerged as a possible regulator of neuronal differentiation and its overexpression has been demonstrated to promote the acquisition of a stem cell-like phenotype in neuroblastoma cells. In this paper, we demonstrated that glioblastoma stem cells (GSCs) isolated from glioblastoma multiforme (GBM) cell lines and patients' specimens as neurospheres are specifically marked by the upregulation of NEU4; in contrast, the expression of NEU4 is very low in non-neurosphere-differentiated GBM cells. We showed that NEU4 silencing by miRNA or a chemical inhibitor of its catalytic activity triggered key events in GSCs, including (a) the activation of the glycogen synthase kinase 3β, with the consequent inhibition of Sonic Hedgehog and Wnt/β-catenin signalling pathways; (b) the decrease of the stem cell-like gene expression and marker signatures, evidenced by the reduction of NANOG, OCT-4, SOX-2, CD133 expression, ganglioside GD3 synthesis, and an altered protein glycosylation profile; and (c) a significant decrease in GSCs survival. Consistent with this finding, increased NEU4 activity and expression induced in the more differentiated GBM cells by the NEU4 agonist thymoquinone increased the expression of OCT-4 and GLI-1. Thus, NEU4 expression and activity appeared to help to determine the molecular signature of GSCs and to be closely connected with their survival properties. Given the pivotal role played by GSCs in GBM lethality, our results strongly suggest that NEU4 inhibition could significantly improve current therapies against this tumour.
Collapse
Affiliation(s)
- I Silvestri
- Department of Medical Biotechnology and Translational Medicine, University of Milan, Segrate (Milan), Italy
| | - F Testa
- Department of Medical Biotechnology and Translational Medicine, University of Milan, Segrate (Milan), Italy
| | - R Zappasodi
- Medical Oncology Department, Fondazione IRCCS Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
| | - C W Cairo
- Alberta Glycomics Center, Department of Chemistry, University of Alberta, Edmonton, Alberta T6G 2G2, Canada
| | - Y Zhang
- Alberta Glycomics Center, Department of Chemistry, University of Alberta, Edmonton, Alberta T6G 2G2, Canada
| | - B Lupo
- Laboratory of Molecular Pharmacology, Institute for Cancer Research and Treatment (IRCC), Candiolo (Torino), Italy
| | - R Galli
- Neural Stem Cell Biology Unit, Division of Regenerative Medicine Stem Cells and Gene Therapy, San Raffaele Scientific Institute, Milan, Italy
| | - M Di Nicola
- Medical Oncology Department, Fondazione IRCCS Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
| | - B Venerando
- Department of Medical Biotechnology and Translational Medicine, University of Milan, Segrate (Milan), Italy
| | - C Tringali
- Department of Medical Biotechnology and Translational Medicine, University of Milan, Segrate (Milan), Italy
| |
Collapse
|